Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG
and long-acting GLP-1 RAs, including exenatide once-weekly, liraglutide, albiglutide, dulaglutide, and semaglutide, known for providing more consistent glycemic control 48,49
Compared with older pharmacologic options, GLP-1 receptor agonists and newer incretin-based therapies generally offer greater average weight reduction, but they also raise specific issues related to gastrointestinal tolerability, long-term continuation, affordability, and access (McGowan et al., 2025)
"There are a whole class of medications that are insulin sensitizers, so perhaps we can develop medications that will allow people to be sensitized to GLP-1s or find formulations of GLP-1, like the longer-acting versions, that avoid the GLP-1 resistance," she said
Riaza Bermudo-SorianoCPerez-RodriguezMMVaquero-LorenzoCBaca-GarciaE
Where do we stand